OBJECTIVE: To evaluate the effect of drug-resistant cytomegalovirus (CMV) on survival among patients with CMV retinitis. DESIGN: Prospective cohort study during 1993 to 2003. PARTICIPANTS: We included 266 patients with AIDS and newly diagnosed CMV retinitis treated with either ganciclovir or foscarnet. METHODS: Data on ganciclovir and foscarnet resistance were obtained from blood and urine specimens collected at regular, predetermined intervals. The effect of resistant CMV on mortality was evaluated with a time-dependent Cox proportional hazard model. MAIN OUTCOME MEASURES: Mortality. RESULTS: The median survival of the entire cohort was 12.6 months. Analysis of risk factors for mortality demonstrated that resistant CMV was associated with an increased mortality (hazard ratio, 1.65; 95% confidence interval, 1.05-2.56; P = 0.032). Among the other parameters tested, only time since AIDS diagnosis was associated significantly with mortality, with a hazard ratio of 1.10 per year since AIDS diagnosis (P = 0.001). CONCLUSIONS: Resistant CMV is associated with increased mortality among patients with AIDS being treated for CMV retinitis. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
OBJECTIVE: To evaluate the effect of drug-resistant cytomegalovirus (CMV) on survival among patients with CMV retinitis. DESIGN: Prospective cohort study during 1993 to 2003. PARTICIPANTS: We included 266 patients with AIDS and newly diagnosed CMV retinitis treated with either ganciclovir or foscarnet. METHODS: Data on ganciclovir and foscarnet resistance were obtained from blood and urine specimens collected at regular, predetermined intervals. The effect of resistant CMV on mortality was evaluated with a time-dependent Cox proportional hazard model. MAIN OUTCOME MEASURES: Mortality. RESULTS: The median survival of the entire cohort was 12.6 months. Analysis of risk factors for mortality demonstrated that resistant CMV was associated with an increased mortality (hazard ratio, 1.65; 95% confidence interval, 1.05-2.56; P = 0.032). Among the other parameters tested, only time since AIDS diagnosis was associated significantly with mortality, with a hazard ratio of 1.10 per year since AIDS diagnosis (P = 0.001). CONCLUSIONS: Resistant CMV is associated with increased mortality among patients with AIDS being treated for CMV retinitis. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Authors: John H Kempen; Douglas A Jabs; Laura A Wilson; James P Dunn; Sheila K West; James Tonascia Journal: Clin Infect Dis Date: 2003-10-14 Impact factor: 9.079
Authors: Douglas A Jabs; Mark L Van Natta; Janet T Holbrook; John H Kempen; Curtis L Meinert; Matthew D Davis Journal: Ophthalmology Date: 2007-01-25 Impact factor: 12.079
Authors: D A Jabs; B K Martin; M S Forman; J P Dunn; J L Davis; D V Weinberg; K K Biron; F Baldanti Journal: J Infect Dis Date: 2000-12-15 Impact factor: 5.226
Authors: Juliet V Spencer; Kristen M Lockridge; Peter A Barry; Gaofeng Lin; Monica Tsang; Mark E T Penfold; Thomas J Schall Journal: J Virol Date: 2002-02 Impact factor: 5.103
Authors: Adriana Weinberg; Douglas A Jabs; Sunwen Chou; Barbara K Martin; Nell S Lurain; Michael S Forman; Clyde Crumpacker Journal: J Infect Dis Date: 2003-02-24 Impact factor: 5.226
Authors: D A Jabs; B K Martin; M S Forman; J P Dunn; J L Davis; D V Weinberg; K K Biron; F Baldanti; H Hu Journal: Am J Ophthalmol Date: 2001-11 Impact factor: 5.258
Authors: Douglas A Jabs; Barbara K Martin; Michael S Forman; Larry Hubbard; J P Dunn; John H Kempen; Janet L Davis; David V Weinberg Journal: Am J Ophthalmol Date: 2003-01 Impact factor: 5.258
Authors: Steven Yeh; Gary Fahle; Farzin Forooghian; Lisa J Faia; Eric D Weichel; J Timothy Stout; Christina J Flaxel; Andreas K Lauer; H Nida Sen; Robert B Nussenblatt Journal: Arch Ophthalmol Date: 2012-01
Authors: Ran He; Bryan T Mott; Andrew S Rosenthal; Douglas T Genna; Gary H Posner; Ravit Arav-Boger Journal: PLoS One Date: 2011-08-31 Impact factor: 3.240
Authors: S N Slavov; F C Vilar; V M D Wagatsuma; R C Santana; A A Machado; B A L da Fonseca; S Kashima; D T Covas Journal: Braz J Med Biol Res Date: 2015-08-04 Impact factor: 2.590